Available in patients’ own communities, novel clinical trials are making an impact in the fight against cancer.
THE WOODLANDS, Texas — US Oncology Research, one of the largest community-based oncology research site management organizations in the United States, is celebrating the significant milestone of contributing to the FDA approval of more than 100 cancer therapies. This achievement is a result of the hard work and dedication to research from more than 165 research locations conducting more than 1600 clinical trials for cancer therapy. More than 80,000 participants have enrolled in clinical trials since 1999.
“US Oncology Research’s core mission is to bring potentially life-saving and life-improving treatments to the community where patients seek care,” said Robert L. Coleman, MD, FACOG, FACS, chief scientific officer, US Oncology Research. “These new interventions come from expert stewardship and execution of clinical research protocols positioned to better understand cancer biology and challenge the status quo. We are, therefore, incredibly proud of this milestone, which reflects the dedication and collective spirit of investigators across The US Oncology Network, committed to defining the next treatment standard. Research is a team sport dedicated to the individual patient.”